- Home
- THFF vs CRGX Comparison
THFF vs CRGX Comparison
Compare THFF & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- CRGX
- Stock Information
- Founded
- THFF 1984
- CRGX 2021
- Country
- THFF United States
- CRGX United States
- Employees
- THFF N/A
- CRGX N/A
- Industry
- THFF Major Banks
- CRGX
- Sector
- THFF Finance
- CRGX
- Exchange
- THFF Nasdaq
- CRGX Nasdaq
- Market Cap
- THFF 599.3M
- CRGX 628.6M
- IPO Year
- THFF N/A
- CRGX 2023
- Fundamental
- Price
- THFF $49.96
- CRGX $3.70
- Analyst Decision
- THFF Hold
- CRGX Hold
- Analyst Count
- THFF 1
- CRGX 7
- Target Price
- THFF $45.00
- CRGX $4.67
- AVG Volume (30 Days)
- THFF 46.4K
- CRGX 1.9M
- Earning Date
- THFF 02-11-2025
- CRGX 03-20-2025
- Dividend Yield
- THFF 4.11%
- CRGX N/A
- EPS Growth
- THFF N/A
- CRGX N/A
- EPS
- THFF 4.00
- CRGX N/A
- Revenue
- THFF $201,592,000.00
- CRGX N/A
- Revenue This Year
- THFF N/A
- CRGX N/A
- Revenue Next Year
- THFF $11.39
- CRGX N/A
- P/E Ratio
- THFF $12.41
- CRGX N/A
- Revenue Growth
- THFF N/A
- CRGX N/A
- 52 Week Low
- THFF $34.58
- CRGX $3.00
- 52 Week High
- THFF $51.87
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- THFF 56.31
- CRGX 20.88
- Support Level
- THFF $47.42
- CRGX $3.00
- Resistance Level
- THFF $49.23
- CRGX $3.88
- Average True Range (ATR)
- THFF 1.35
- CRGX 0.92
- MACD
- THFF 0.26
- CRGX -1.00
- Stochastic Oscillator
- THFF 75.81
- CRGX 5.99
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services, and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.